These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 7609360

  • 21. [Chemotherapy of invasive bladder cancer].
    Kotake T.
    Gan To Kagaku Ryoho; 1991 Nov; 18(14):2375-82. PubMed ID: 1952956
    [Abstract] [Full Text] [Related]

  • 22. A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma.
    Oh WK, Manola J, Richie JP, Loughlin KR, Kantoff PW.
    Cancer; 1999 Oct 01; 86(7):1329-34. PubMed ID: 10506721
    [Abstract] [Full Text] [Related]

  • 23. [Combination chemotherapy of urothelial cancer with cisplatin, cyclophosphamide, doxorubicin and peplomycin: treatment of advanced cases and adjuvant chemotherapy after radical operation].
    Seguchi T, Sakaguchi H, Kajikawa H, Nishioka T.
    Gan To Kagaku Ryoho; 1987 Mar 01; 14(3 Pt 1):600-5. PubMed ID: 2435245
    [Abstract] [Full Text] [Related]

  • 24. [Low dose COMPE. Cisplatin, vincristine, methotrexate, peplomycin, etoposide chemotherapy for advanced testicular cancer].
    Ueda T, Yamauchi T, Kawai T, Ohono Y, Kawakami S, Yonese J.
    Nihon Hinyokika Gakkai Zasshi; 1994 Apr 01; 85(4):626-31. PubMed ID: 7514699
    [Abstract] [Full Text] [Related]

  • 25. Carboplatin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer. A phase II trial.
    Boccardo F, Pace M, Guarneri D, Canobbio L, Curotto A, Martorana G.
    Cancer; 1994 Apr 01; 73(7):1932-6. PubMed ID: 8137220
    [Abstract] [Full Text] [Related]

  • 26. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium.
    Sternberg CN, Yagoda A, Scher HI, Watson RC, Ahmed T, Weiselberg LR, Geller N, Hollander PS, Herr HW, Sogani PC.
    J Urol; 1985 Mar 01; 133(3):403-7. PubMed ID: 4038749
    [Abstract] [Full Text] [Related]

  • 27. Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer.
    Necchi A, Mariani L, Giannatempo P, Raggi D, Farè E, Nicolai N, Piva L, Biasoni D, Catanzaro M, Torelli T, Stagni S, Maffezzini M, Pizzocaro G, De Braud FG, Gianni AM, Salvioni R.
    Clin Genitourin Cancer; 2014 Jun 01; 12(3):203-209.e1. PubMed ID: 24394493
    [Abstract] [Full Text] [Related]

  • 28. [Chemotherapy for advanced urothelial cancer patients with a combination of low-dose consecutive cisplatin and etoposide].
    Hashimoto H, Tokumitsu M, Morikawa M, Numata A, Yachiku S, Iuchi H, Yamauchi K.
    Gan To Kagaku Ryoho; 1996 Jun 01; 23(7):941-4. PubMed ID: 8678548
    [No Abstract] [Full Text] [Related]

  • 29. Three-drug combination chemotherapy for advanced urothelial tract carcinoma.
    Ohshima S, Ono Y, Fujita T, Aso Y.
    Cancer Chemother Pharmacol; 1987 Jun 01; 20 Suppl():S20-3. PubMed ID: 2444354
    [Abstract] [Full Text] [Related]

  • 30. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial.
    Pectasides D, Visvikis A, Aspropotamitis A, Halikia A, Karvounis N, Dimitriadis M, Athanassiou A.
    Eur J Cancer; 2000 Jan 01; 36(1):74-9. PubMed ID: 10741298
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [Alternative combination chemotherapy with mitomycin C, vincristine, methotrexate, 5-fluorouracil, cis-platinum and adriamycin for adenocarcinoma of the lung].
    Xing FY, Liu WH, Dong W, Zhang SL, Gu BW, Okazaki K, Naito H, Inoue T, Wu JT, Tamura S.
    Gan To Kagaku Ryoho; 1993 Feb 01; 20(2):259-63. PubMed ID: 8434964
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
    Varveris H, Delakas D, Anezinis P, Haldeopoulos D, Mazonakis M, Damilakis J, Metaxaris G, Chondros N, Mavromanolakis E, Daskalopoulos G, Dimitrakopoulos A, Kranidis A.
    Anticancer Res; 1997 Feb 01; 17(6D):4771-80. PubMed ID: 9494605
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Adjuvant methotrexate, vinblastine and cisplatin chemotherapy for invasive transitional cell carcinoma: Taiwan experience.
    Wei CH, Hsieh RK, Chiou TJ, Chen KK, Chang LS, Chen PM.
    J Urol; 1996 Jan 01; 155(1):118-21. PubMed ID: 7490806
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Chemotherapy for advanced urothelial tract tumors: the M-VAC regimen.
    Sternberg CN, Yagoda A, Scher HI.
    Prog Clin Biol Res; 1988 Jan 01; 277():45-51. PubMed ID: 3054909
    [No Abstract] [Full Text] [Related]

  • 39. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial.
    Loehrer PJ, Elson P, Dreicer R, Hahn R, Nichols CR, Williams R, Einhorn LH.
    J Clin Oncol; 1994 Mar 01; 12(3):483-8. PubMed ID: 7509853
    [Abstract] [Full Text] [Related]

  • 40. Cisplatin, ifosfamide, methotrexate and vinblastine combination chemotherapy for metastatic urothelial cancer.
    Kyriakakis Z, Dimopoulos MA, Kostakopoulos A, Karayiannis A, Sofras F, Zervas A, Giannopoulos A, Dimopoulos C.
    J Urol; 1997 Aug 01; 158(2):408-11. PubMed ID: 9224313
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.